Dipti Patel-Donnelly, MD
Position
Medical Oncologist
Board Certification
Medical Oncology, Hematology
Accepting new patients
4.94 out of 5
147 Reviews
Our understanding of the mechanisms and driving mutations of cancer are rapidly evolving. We use our medical knowledge, judgement, and vast experience to offer the most personalized, comprehensive, and compassionate care to guide every person through this challenging journey together.
Dipti Patel-Donnelly, MDBio
Dipti Patel-Donnelly, MD
Oncologist and Assistant Professor of Oncology at Johns Hopkins University
Dr. Patel-Donnelly is dual board-certified in medical oncology and hematology. She completed her fellowship in Medical Oncology and Hematology at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital/Massachusetts General Hospital at Harvard Medical School. Dr. Patel-Donnelly received her Doctorate of Medicine and completed her Internal Medicine Internship and Residency from the Mount Sinai School of Medicine in New York, New York, and she is a magna cum laude graduate in biochemistry with honors and independent research from Binghamton University in Binghamton, New York.
Dr. Patel-Donnelly is the President of Virginia Cancer Specialists and has played an active role in the local and medical communities. Dr. Patel-Donnelly holds memberships and appointments in multiple organizations. Dr. Patel-Donnelly is currently an Assistant Professor, in the Department of Oncology at Johns Hopkins University. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Society of Hematology, and the Medical Society of Virginia. Focusing on a special interest in hematologic malignancies, brain tumors, and stem cell transplant, Dr. Patel-Donnelly has become highly involved in local tumor boards and has served as Section Chief of Hematology/Oncology at Inova Fairfax Hospital and has held a Hematology/Oncology Faculty Clerkship appointment at Virginia Commonwealth University. Dr. Patel-Donnelly has also received multiple awards and honors which include the Harvard Partners in Excellence Award, Leukemia and Lymphoma Society’s “Relentless for a Cure” award, Excellence in Teaching Awards, National Institutes of Health Research Fellowship, NASE Achievement Scholarship, and Distinguished Honors and Independent Research in Biochemistry. Dr. Patel-Donnelly has been consistently named as a Top Doctor in publications such as Northern Virginia Magazine and Washingtonian magazine. Additionally, she has been listed as a “Castle Connolly Mid-Atlantic Top Doctor and a Washington Post Super Doctor”. Dr. Patel-Donnelly is a published author and has spoken both at local educational events and at national and local news interviews.
Dr. Patel-Donnelly is a member of several, prestigious, national committees. She is Chairwoman of the highly-selective, national panel tasked with writing/selecting Oncology Board questions for the American Board of Internal Medicine, which certifies that medical oncologists have a competent fund of knowledge to be board-certified and practice. She has also been selected to serve on the American Society of Clinical Oncology (ASCO) Leukemia Guideline Committee, which reviews current research evidence and makes uniform guidelines on treating leukemia.
Dr. Patel-Donnelly lives in Northern Virginia with her husband and two children. She enjoys spending time with her family, cooking, running, traveling, and reading.
Credentials
Fellowship
Dana-Farber Cancer Institute/Brigham and Women’s Hospital/Massachusetts General Hospital Medical Oncology and Hematology
Internship
Mount Sinai School of Medicine
Medical School
Mount Sinai School of Medicine
Residency
Mount Sinai School of Medicine
College
Binghamton University
Special Interest
Hematological malignancies (leukemia, lymphoma, multiple myeloma), brain tumors
Languages
English, Gujarati
Awards
Northern Virginia Magazine Top Doctor
February 1, 2024
Northern Virginia Magazine Top Doctor
February 1, 2023
Northern Virginia Magazine Top Doctor
February 1, 2022
Northern Virginia Magazine Top Doctor
February 1, 2021
Northern Virginia Magazine Top Doctor
February 1, 2020
Castle Connolly #1 Physician Practice
January 1, 2024
Castle Connolly #1 Physician Practice
January 1, 2021
Castle Connolly #1 Physician Practice
January 1, 2020
Arlington Magazine Awards Top Doctor
July 1, 2024
Washingtonian Magazine Top Doctor
November 1, 2023
Washingtonian Magazine Top Doctor
November 1, 2021
Washingtonian Magazine Top Doctor
November 1, 2020
Physician Publications
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy in older patients ineligible for chemotherapy
November 1, 2023
Read MoreSafety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
January 22, 2022
Read MoreFrontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients
December 6, 2020
Read MoreMore Publications by Dipti Patel-Donnelly, MD
December 6, 2020
Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Clinical Studies in Hodgkin Lymphoma
Read MoreAugust 1, 2019
Entospletinib Monotherapy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Previously Treated With B-cell Receptor Inhibitors: Results of a Phase 2 Study
Read MoreJanuary 20, 2019
Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline
Read MoreJanuary 11, 2019
Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study
Read MoreJanuary 1, 2019
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Read MoreAugust 18, 2018
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
Read MoreDecember 3, 2018
Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline
Read MoreDecember 28, 2017
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL
Read MoreApril 1, 2017
WALDENSTRÖM'S MACROGLOBULINEMIA MASQUERADING AS BIRDSHOT CHORIORETINOPATHY.
Read MoreJanuary 16, 2014
Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy
Read MoreJune 2, 2013
Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).
Read MoreNovember 15, 2012
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Read MoreDecember 11, 2011
Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study
Read MoreOctober 20, 2009
Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
Read MoreJanuary 1, 2003
The dynamics of GPIIb/IIIa-mediated platelet-platelet interactions in platelet adhesion/thrombus formation on collagen in vitro as revealed by videomicroscopy
Read MoreWhat Patients Say
Location
ALL LOCATIONS
FAIRFAX OFFICE
Hours of Operation
Monday through Friday
8:30 a.m. to 5:00 p.m
Phone:
(571) 350-8400
Fax:
(703) 280-9596
Address:
8613 Route 29
Fairfax, VA 22031
